\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes ERC MSCA Research Infrastructures EIC EITInnoNext is a two-year project funded under the European Innovation Council (EIC) with the objective to match visiting researchers with start-ups or SMEs which host the visiting researchers during an internship with a duration of 3 up to 6 months (depending on the EU programme).
The researchers and companies involved are funded by an EU funding programme (ERC, MSCA, RI, EIT or EIC). More detailed information about eligible visiting researchers and hosting start-ups and SMEs is available on the InnoNext website under the section who can apply. The financial support of these internships depends on the EU programme that the visiting researcher is affiliated with.
Within the duration of the InnoNext project it is expected to fund 600 internships. The call for applications is now open for visiting talents and for hosting companies.
All information about this new initiative is available on the project’s website. The resources section and FAQs offer a comprehensive overview already now. In case after exploring the suitability of (hosting) the internship any further questions arise the project partners can be contacted directly.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
